DD148719A5 - Kontrastmittel fuer die angiographie und verfahren zu ihrer herstellung - Google Patents
Kontrastmittel fuer die angiographie und verfahren zu ihrer herstellung Download PDFInfo
- Publication number
- DD148719A5 DD148719A5 DD80218635A DD21863580A DD148719A5 DD 148719 A5 DD148719 A5 DD 148719A5 DD 80218635 A DD80218635 A DD 80218635A DD 21863580 A DD21863580 A DD 21863580A DD 148719 A5 DD148719 A5 DD 148719A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- compound
- item
- contrast agent
- perfluorocarbon
- carbon atoms
- Prior art date
Links
- 238000002583 angiography Methods 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 11
- 239000002872 contrast media Substances 0.000 claims abstract description 72
- 239000000839 emulsion Substances 0.000 claims abstract description 36
- -1 perfluorocarbon compound Chemical class 0.000 claims abstract description 32
- 150000005527 organic iodine compounds Chemical class 0.000 claims abstract description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
- 239000001301 oxygen Substances 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 150000001722 carbon compounds Chemical class 0.000 claims abstract 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 7
- 229950011087 perflunafene Drugs 0.000 claims description 7
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 claims description 7
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 4
- 229960005423 diatrizoate Drugs 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- UCPVOMHRDXMAIZ-UHFFFAOYSA-M sodium acetrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C=C(I)C(C([O-])=O)=C1I UCPVOMHRDXMAIZ-UHFFFAOYSA-M 0.000 claims description 4
- LWRNQOBXRHWPGE-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8a-heptadecafluoro-8-(trifluoromethyl)naphthalene Chemical class FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(C(F)(F)F)(F)C(F)(F)C(F)(F)C(F)(F)C21F LWRNQOBXRHWPGE-UHFFFAOYSA-N 0.000 claims description 3
- 229950011473 sodium acetrizoate Drugs 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- ABDBNWQRPYOPDF-UHFFFAOYSA-N carbonofluoridic acid Chemical compound OC(F)=O ABDBNWQRPYOPDF-UHFFFAOYSA-N 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- HXLVCCRPDYIRRX-UHFFFAOYSA-N iodoamine Chemical compound IN HXLVCCRPDYIRRX-UHFFFAOYSA-N 0.000 claims 1
- 238000002156 mixing Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- XZNXVSDNACTASG-RZNNTOFGSA-M sodium;3,5-diacetamido-2,4,6-triiodobenzoate;3,5-diacetamido-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I XZNXVSDNACTASG-RZNNTOFGSA-M 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 6
- UKIYDXCFKFLIMU-UHFFFAOYSA-M Isopaque Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I UKIYDXCFKFLIMU-UHFFFAOYSA-M 0.000 description 5
- RERHJVNYJKZHLJ-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;2-(3,5-diiodo-4-oxopyridin-1-yl)acetate Chemical compound OCCNCCO.OC(=O)CN1C=C(I)C(=O)C(I)=C1 RERHJVNYJKZHLJ-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- JAJLKEVKNDUJBG-UHFFFAOYSA-N perfluorotripropylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F JAJLKEVKNDUJBG-UHFFFAOYSA-N 0.000 description 5
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 5
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 5
- VLHUSFYMPUDOEL-WZTVWXICSA-N Iothalamate meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VLHUSFYMPUDOEL-WZTVWXICSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 4
- 229950008618 perfluamine Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010047095 Vascular pain Diseases 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 229940039231 contrast media Drugs 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 3
- 229960004901 iodamide Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- COCJIVDXXCJXND-UHFFFAOYSA-M sodium;iodomethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CI COCJIVDXXCJXND-UHFFFAOYSA-M 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- DLTCLUPPEMEAGB-UHFFFAOYSA-N 3-carbamoyl-2,4,6-triiodobenzoic acid Chemical compound NC(=O)C1=C(I)C=C(I)C(C(O)=O)=C1I DLTCLUPPEMEAGB-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- PVBALTLWZVEAIO-UHFFFAOYSA-N diodone Chemical compound OC(=O)CN1C=C(I)C(=O)C(I)=C1 PVBALTLWZVEAIO-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- BPHQIXJDBIHMLT-UHFFFAOYSA-N perfluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BPHQIXJDBIHMLT-UHFFFAOYSA-N 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- WCIMWHNSWLLELS-UHFFFAOYSA-M sodium;3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoate Chemical compound [Na+].CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I WCIMWHNSWLLELS-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PSJKAILWKIKKNU-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4-nonafluoro-n-(1,1,2,2,3,3,4,4,4-nonafluorobutyl)-n-(trifluoromethyl)butan-1-amine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F PSJKAILWKIKKNU-UHFFFAOYSA-N 0.000 description 1
- WBQMKAKILKYGRY-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,5-undecafluoro-N,N-bis(1,1,2,2,2-pentafluoroethyl)pentan-1-amine Chemical compound FC(F)(F)C(F)(F)N(C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F WBQMKAKILKYGRY-UHFFFAOYSA-N 0.000 description 1
- RKIMETXDACNTIE-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6-dodecafluorocyclohexane Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F RKIMETXDACNTIE-UHFFFAOYSA-N 0.000 description 1
- XZZGMFAUFIVEGL-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6-undecafluoro-6-(1,1,2,2,3,3,4,4,4-nonafluorobutyl)cyclohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F XZZGMFAUFIVEGL-UHFFFAOYSA-N 0.000 description 1
- SIJZIPMRLFRVHV-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5-nonafluoro-5,6,6-tris(trifluoromethyl)cyclohexane Chemical compound FC(F)(F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(C(F)(F)F)C(F)(F)F SIJZIPMRLFRVHV-UHFFFAOYSA-N 0.000 description 1
- YDSHWJILVOQURX-UHFFFAOYSA-N 1,2,2,3,3,4,4,5,5,6,6-undecafluoro-n,n-bis(1,1,2,2,2-pentafluoroethyl)cyclohexan-1-amine Chemical compound FC(F)(F)C(F)(F)N(C(F)(F)C(F)(F)F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F YDSHWJILVOQURX-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- COBIOCPXKOZHSU-UHFFFAOYSA-N 10-[(1-methylpiperidin-1-ium-3-yl)methyl]phenothiazine;acetate Chemical compound CC(O)=O.C1N(C)CCCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 COBIOCPXKOZHSU-UHFFFAOYSA-N 0.000 description 1
- GDCXYFJTTYCIKU-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6-decafluoro-1-(1,1,2,2,3,3,4,4,5,5,5-undecafluoropentyl)piperidine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)N1C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F GDCXYFJTTYCIKU-UHFFFAOYSA-N 0.000 description 1
- GRVJYLQOWJWEFK-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6-decafluoro-1-(1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexyl)piperidine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)N1C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F GRVJYLQOWJWEFK-UHFFFAOYSA-N 0.000 description 1
- CBUDGIQWHQHTHD-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6-nonafluoro-6-(1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexyl)oxane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)OC(F)(F)C(F)(F)C(F)(F)C1(F)F CBUDGIQWHQHTHD-UHFFFAOYSA-N 0.000 description 1
- FCAKFMGNFPPPSH-UHFFFAOYSA-N 2,2,3,3,4,4,5-heptafluoro-5-(1,1,2,2,3,3,4,4,5,5,5-undecafluoropentyl)oxolane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)OC(F)(F)C(F)(F)C1(F)F FCAKFMGNFPPPSH-UHFFFAOYSA-N 0.000 description 1
- ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical class OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 1
- CRVYPNHLIAWRNV-UHFFFAOYSA-M 2,4,6-triiodobenzoate Chemical compound [O-]C(=O)C1=C(I)C=C(I)C=C1I CRVYPNHLIAWRNV-UHFFFAOYSA-M 0.000 description 1
- PQVTXVSKVXKTEN-WZTVWXICSA-N 2-(3,5-diiodo-4-oxopyridin-1-yl)acetic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN1C=C(I)C(=O)C(I)=C1 PQVTXVSKVXKTEN-WZTVWXICSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UYIPQECISAQMIU-WZTVWXICSA-N 3-acetamido-5-(acetamidomethyl)-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UYIPQECISAQMIU-WZTVWXICSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- WRUDQVSBNXFACF-UHFFFAOYSA-N FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)N1C(F)(F)C(F)(F)OC(F)(F)C1(F)F Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)N1C(F)(F)C(F)(F)OC(F)(F)C1(F)F WRUDQVSBNXFACF-UHFFFAOYSA-N 0.000 description 1
- DSXQNQQCDMBVOD-UHFFFAOYSA-N FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)N1C(F)(F)C(F)(F)OC(F)(F)C1(F)F Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)N1C(F)(F)C(F)(F)OC(F)(F)C1(F)F DSXQNQQCDMBVOD-UHFFFAOYSA-N 0.000 description 1
- QRGKREXBRIWEMS-UHFFFAOYSA-N FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N1C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N1C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F QRGKREXBRIWEMS-UHFFFAOYSA-N 0.000 description 1
- QFYNLSCJBREZMB-UHFFFAOYSA-N FC(F)(F)C(F)(F)C(F)(F)C1(C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F Chemical compound FC(F)(F)C(F)(F)C(F)(F)C1(C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F QFYNLSCJBREZMB-UHFFFAOYSA-N 0.000 description 1
- CJAFXLJLGHAEOC-UHFFFAOYSA-N FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F Chemical compound FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CJAFXLJLGHAEOC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960001845 diodone Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960003695 methiodal Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- FRZFEPXEUZSBLA-UHFFFAOYSA-N perfluoroadamantane Chemical compound FC1(F)C(C2(F)F)(F)C(F)(F)C3(F)C(F)(F)C1(F)C(F)(F)C2(F)C3(F)F FRZFEPXEUZSBLA-UHFFFAOYSA-N 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229950000550 sodium metrizoate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0476—Oxygenated solutions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/90—In vivo diagnostic or in vivo test agent which contains an additional ingredient to reduce the toxicity or side effects of the active ingredient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Meat, Egg Or Seafood Products (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP743779A JPS55100312A (en) | 1979-01-25 | 1979-01-25 | Contrast medium for blood vessel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD148719A5 true DD148719A5 (de) | 1981-06-10 |
Family
ID=11665829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD80218635A DD148719A5 (de) | 1979-01-25 | 1980-01-24 | Kontrastmittel fuer die angiographie und verfahren zu ihrer herstellung |
Country Status (22)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4490351A (en) * | 1982-03-15 | 1984-12-25 | Children's Hospital Medical Center | Methods of treating disorders of an eye with liquid perfluorocarbons |
| US4452818A (en) * | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
| JPS5946230A (ja) * | 1982-09-08 | 1984-03-15 | Green Cross Corp:The | 造影剤 |
| US4640833A (en) * | 1983-02-28 | 1987-02-03 | Adamantech, Inc. | Use of perfluorobromoalkyl ethers as X-ray contrast agents |
| US4567034A (en) * | 1984-09-07 | 1986-01-28 | E. R. Squibb & Sons, Inc. | Esters of diatrizoic acid as X-ray contrast agents |
| US4767610A (en) * | 1984-10-19 | 1988-08-30 | The Regents Of The University Of California | Method for detecting abnormal cell masses in animals |
| US4680171A (en) * | 1985-03-15 | 1987-07-14 | William Shell | Visualization of a bloodstream circulation with biodegradable microspheres |
| US5284645A (en) * | 1987-08-05 | 1994-02-08 | Alliance Pharmaceutical Corp. | Fluorocarbon emulsions containing amino acid based anti-inflamatory agents and buffer systems |
| US5847009A (en) | 1986-01-14 | 1998-12-08 | Alliance Pharmaceutical Corp. | Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions |
| US5514720A (en) * | 1986-07-09 | 1996-05-07 | Hemagen/Pfc | Stable emulsions of highly fluorinated organic compounds |
| US5684050A (en) * | 1986-01-24 | 1997-11-04 | Hemagen/Pfc | Stable emulsions of highly fluorinated organic compounds |
| EP0417104A4 (en) * | 1988-03-11 | 1991-10-30 | Alpha Therapeutic Corporation | Perfluorochemical emulsion with stabilized vesicles |
| US5061484A (en) * | 1988-03-11 | 1991-10-29 | Alpha Therapeutic Corporation | Perfluorochemical emulsion with stabilized vesicles |
| US5171755A (en) * | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
| GB8919929D0 (en) * | 1989-09-04 | 1989-10-18 | Nycomed As | Compositions |
| US5403575A (en) * | 1991-12-12 | 1995-04-04 | Hemagen/Pfc | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them |
| US5350359A (en) * | 1992-07-16 | 1994-09-27 | Temple University Of The Commonwealth System Of Higher Education | Control, treatment and/or diagnosis of physiological conditions with degassed perfluorocarbon liquid |
| US5741248A (en) * | 1995-06-07 | 1998-04-21 | Temple University-Of The Commonwealth System Of Higher Education | Fluorochemical liquid augmented cryosurgery |
| DE19731300C1 (de) * | 1997-07-11 | 1999-01-21 | Schering Ag | Perfluoralkylgruppenhaltige Trijodaromaten, Verfahren zu deren Herstellung und deren Verwendung als Kontrastmittel |
| DE19731591C2 (de) * | 1997-07-17 | 1999-09-16 | Schering Ag | Pharmazeutische Mittel enthaltend perfluoralkylgruppenhaltige Trijodaromaten und ihre Verwendung in der Tumortherapie und interventionellen Radiologie |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2832722A (en) * | 1953-07-15 | 1958-04-29 | Ortho Pharma Corp | Radiopaque formulation comprising pvp as bodying agent |
| DE2163191C2 (de) * | 1970-12-21 | 1982-07-01 | The University of Illinois Foundation, Urbana, Ill. | Röntgenkontrastmittel |
| US3975512A (en) * | 1970-12-21 | 1976-08-17 | University Of Illinois Foundation | Non-toxic brominated perfluorocarbons radiopaque agents |
| US3818229A (en) * | 1970-12-21 | 1974-06-18 | Univ Illinois | Radiopaque agents comprising brominated perfluorocarbons |
| BE788054A (fr) * | 1971-08-26 | 1973-02-26 | Bracco Ind Chimica Spa | Nouvel agent de contraste radiographique et procede pour le preparer |
| JPS5331209B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1973-10-05 | 1978-09-01 | ||
| US4073879A (en) * | 1974-08-26 | 1978-02-14 | University Of Illinois Foundation | Brominated perfluorocarbon radiopaque agents |
| US3975572A (en) * | 1975-12-22 | 1976-08-17 | Formica Corporation | Thin, tough, stable, mar-resistant laminate |
| JPS5835485B2 (ja) * | 1976-02-03 | 1983-08-03 | 株式会社ミドリ十字 | 酸素運搬輸液 |
-
1979
- 1979-01-25 JP JP743779A patent/JPS55100312A/ja active Granted
-
1980
- 1980-01-03 DK DK003580A patent/DK156621C/da not_active IP Right Cessation
- 1980-01-04 SE SE8000074A patent/SE445973B/sv not_active IP Right Cessation
- 1980-01-09 AR AR279585A patent/AR229084A1/es active
- 1980-01-14 NZ NZ192600A patent/NZ192600A/xx unknown
- 1980-01-15 US US06/112,275 patent/US4285928A/en not_active Expired - Lifetime
- 1980-01-16 GB GB8001418A patent/GB2041221B/en not_active Expired
- 1980-01-16 AU AU54647/80A patent/AU517412B2/en not_active Ceased
- 1980-01-17 ZA ZA80287A patent/ZA80287B/xx unknown
- 1980-01-17 NL NLAANVRAGE8000310,A patent/NL187894C/xx active Search and Examination
- 1980-01-17 IL IL59149A patent/IL59149A/xx unknown
- 1980-01-18 IT IT47643/80A patent/IT1143008B/it active
- 1980-01-21 DE DE3002004A patent/DE3002004C2/de not_active Expired
- 1980-01-22 LU LU82103A patent/LU82103A1/fr unknown
- 1980-01-23 FI FI800195A patent/FI77984C/fi not_active IP Right Cessation
- 1980-01-23 CH CH52080A patent/CH646062A5/de not_active IP Right Cessation
- 1980-01-23 NO NO800164A patent/NO152863C/no unknown
- 1980-01-24 BE BE0/199088A patent/BE881324A/fr not_active IP Right Cessation
- 1980-01-24 DD DD80218635A patent/DD148719A5/de not_active IP Right Cessation
- 1980-01-24 FR FR8001509A patent/FR2447195A1/fr active Granted
- 1980-01-24 AT AT0039080A patent/AT369266B/de not_active IP Right Cessation
- 1980-01-25 CA CA000344443A patent/CA1140849A/en not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD148719A5 (de) | Kontrastmittel fuer die angiographie und verfahren zu ihrer herstellung | |
| DE3850012T2 (de) | Emulsionen von Fluorkohlenwasserstoffen für "in vivo"-Verwendung. | |
| DE3785054T2 (de) | Stabile emulsionen von stark fluorierten, organischen verbindungen. | |
| DE3503279C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE69218241T2 (de) | Arzneistofformulierung zur parenteralen anwendung | |
| DE60028384T2 (de) | Propofol enthaltende anästhetische zusammensetzung zur intravenösen injektion | |
| DE69534326T2 (de) | Hepatocyt-selektive öl-in-wasser emulsion | |
| DE69231503T2 (de) | In hohem masse fluorierte, chlorsubstituierte organische verbindungen enthaltende emulsionen und methoden zu deren herstellung und verwendung | |
| DE19543271A1 (de) | Orales pharmazeutisches Präparat | |
| DD212897A5 (de) | Verfahren zur herstellung einer topisch applizierbaren pharmazeutischen zusammensetzung | |
| DE69320405T2 (de) | Ophthalmische Zusammensetzungen enthaltend als Wirkstoff Vitamin-E oder Ester davon | |
| DE60308888T2 (de) | Injizierbare 2,6-diisopropylphenol enthaltende anästhetische zusammensetzung und verfahren | |
| DE69427981T2 (de) | Verkapselter arzneistoff | |
| DE3785849T2 (de) | Jod enthaltende emulsion. | |
| CH643456A5 (de) | Pharmazeutische zubereitung. | |
| DE3390172T1 (de) | Perfluorkohlenstoff-Emulsionen, deren Herstellung und deren Verwendung in der Therapie | |
| DE69021289T2 (de) | Angiographisches Adjuvans. | |
| DE19900054A1 (de) | Taxane enthaltende stabile und sterile Emulsion und Verfahren zu ihrer Herstellung | |
| DE3884945T2 (de) | Emulsion für parenterale verabreichung. | |
| DE69001513T2 (de) | Polyprenylverbindung enthaltende Zusammensetzung für weiche Kapseln. | |
| DE69428967T2 (de) | Pharmazeutische emulsionen, die bioaktive steroide enthalten | |
| EP2142169B1 (de) | Wässrige pharmazeutische zubereitung | |
| DE3509741A1 (de) | Orale dosierungsform von etoposid | |
| DE60222843T2 (de) | Hydrophobe Iodverbindung enthaltendes Liposom und dieses enthaltendes Röntgenkontrastmittel | |
| DE69307197T2 (de) | Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |